IQVIA’s Latest Clinical Study Update: A New Hope for Peripheral Arterial Disease

IQVIA Holdings ((IQV)) announced an update on their ongoing clinical study.

IQVIA Holdings (IQV) has recently provided an update on a clinical study titled ‘Prospective, Multi-center, Single-arm Investigational Study of SWM-831 to Treat Moderate and Severely Calcified Femoropopliteal Arteries.’ The study aims to evaluate the safety and effectiveness of the SWM-831 device in treating peripheral arterial disease, specifically targeting calcified femoropopliteal arteries. This research is significant as it could offer new treatment options for patients with this condition.

The intervention being tested is the Peripheral Intravascular Lithotripsy (IVL) device, known as SWM-831. This device is designed to perform lithotripsy-enhanced balloon dilatation of calcified lesions in the peripheral vasculature, including the femoropopliteal arteries.

The study follows an interventional design with a single-group model, focusing on treatment as its primary purpose. There is no masking involved, meaning all participants and researchers are aware of the treatment being administered.

Key dates for the study include its start date on April 7, 2025, and the last update on June 20, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.

The market implications of this study are significant for Shockwave Medical, Inc., the lead sponsor. A successful outcome could enhance their market position and positively influence investor sentiment. Competitors in the medical device industry will be closely monitoring these developments.

The study is currently ongoing, with further details available on the ClinicalTrials portal.